Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

White Plains, New York 10605


Emotionally labile, depressed participants with multiple sclerosis treated with escitalopram will have a greater reduction in emotional lability scores and in their psychological distress scores than those who are randomized to receive placebo.

Study summary:

Patients with multiple sclerosis who are experiencing mood lability and symptoms of depression will be randomized to receive either escitalopram 10mg/day or placebo tablets for a period of 6 weeks. It is hypothesized that patients receiving medication will experience a greater normalization of their emotional instability and a greater reduction in their depressive symptoms at the end of the six-week trial than those who are not receiving medication.


Inclusion Criteria: - Clinical diagnosis of multiple sclerosis - Having mild to moderate depressive symptoms, with or without emotional lability - Experiencing psychological distress Exclusion Criteria: - Meeting DSM-IV diagnostic criteria for Major Depressive Disorder or another Axis 1 diagnosis - Cognitive impairment - The presence of an unstable medical illness that might preclude completion of the study -



Primary Contact:

Principal Investigator
Barnett S Meyers, MD
Weill Medical College of Cornell University

Backup Contact:


Location Contact:

White Plains, New York 10605
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.